Ultevursen Market Summary

Key Factors Driving Ultevursen Growth

1. Precision RNA therapy targeting USH2A exon 13 (disease-modifying)

• Ultevursen is designed to skip exon 13 in USH2A mRNA, restoring production of a functional protein (reported in clinical publications and company disclosures).
• USH2A mutations are among the most common genetic causes of retinitis pigmentosa and Usher syndrome.

2. Positive Phase I/II clinical efficacy signals

• Phase I/II Stellar trial showed:

o Improvements in best-corrected visual acuity (BCVA)

o Trends toward improvement in retinal sensitivity and visual function (company presentations and publications)

• Long-term follow-up demonstrated durability of effect up to 2 years

3. Advancement into pivotal development (de-risking)

• Ultevursen is progressing toward Phase II/III (LUNA trial) in USH2A exon 13 patients (company updates and press releases).
• Regulatory alignment achieved with FDA and EMA on trial design.

4. Significant unmet need in USH2A retinal disease

• USH2A mutations account for:

o ~12–25% of autosomal recessive RP cases (literature/PubMed estimates)

• No approved therapies currently exist for this population.

5. Favorable safety and repeat dosing potential

• Intravitreal ASO therapy allows:

o Repeat dosing (e.g., quarterly injections)

o Avoids permanent genomic modification (vs gene therapy)

• Clinical data showed generally well tolerated profile in early trials.

Ultevursen Recent Developments

In December 2023, Théa acquired ProQR’s ophthalmology assets, which included Ultevursen and Sepofarsen, an emerging RNA therapy for patients with Leber congenital amaurosis type 10 caused by the IVS26 mutation in the CEP290 gene. Théa launched its Sepul Bio business unit to continue clinical development of Ultevursen and Sepofarsen.

“Ultevursen Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Ultevursen for potential indication like Retinitis pigmentosa and Usher syndromes in the 7MM. A detailed picture of Ultevursen’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Ultevursen for potential indications. The Ultevursen market report provides insights about Ultevursen’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Ultevursen performance, future market assessments inclusive of the Ultevursen market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Ultevursen sales forecasts, along with factors driving its market.

Ultevursen Drug Summary

Ultevursen is an investigational antisense oligonucleotide therapy designed to treat inherited retinal diseases caused by mutations in the USH2A gene, a common genetic cause of retinitis pigmentosa and Usher syndrome type 2. Developed by ProQR Therapeutics, Ultevursen works by selectively binding to mutant USH2A pre-mRNA to modulate splicing and restore the production of a functional usherin protein, thereby targeting the underlying genetic defect rather than only addressing symptoms. The therapy is administered via intravitreal injection, allowing direct delivery to retinal cells, and is designed to preserve photoreceptor structure and function, potentially slowing disease progression and vision loss. Ultevursen is currently in clinical development, with studies evaluating its safety, tolerability, and efficacy in improving visual outcomes in patients with USH2A-mediated retinal degeneration, positioning it as a promising RNA-based precision therapy in ophthalmology. The report provides Ultevursen’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Ultevursen Market Report

The report provides insights into:

• A comprehensive product overview including the Ultevursen MoA, description, dosage and administration, research and development activities in potential indication like Retinitis pigmentosa and Usher syndromes.
• Elaborated details on Ultevursen regulatory milestones and other development activities have been provided in Ultevursen market report.
• The report also highlights Ultevursen‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Ultevursen market report also covers the patents information, generic entry and impact on cost cut.
• The Ultevursen market report contains current and forecasted Ultevursen sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Ultevursen market report also features the SWOT analysis with analyst views for Ultevursen in potential indications.

Methodology

The Ultevursen market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Ultevursen Analytical Perspective by DelveInsight

• In-depth Ultevursen Market Assessment

This Ultevursen sales market forecast report provides a detailed market assessment of Ultevursen for potential indication like Retinitis pigmentosa and Usher syndromes in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Ultevursen sales data uptil 2034.

• Ultevursen Clinical Assessment

The Ultevursen market report provides the clinical trials information of Ultevursen for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Ultevursen Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Ultevursen Market Potential & Revenue Forecast

• Projected market size for the Ultevursen and its key indications
• Estimated Ultevursen sales potential (Ultevursen peak sales forecasts)
• Ultevursen Pricing strategies and reimbursement landscape

Ultevursen Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Ultevursen Market positioning compared to existing treatments
• Ultevursen Strengths & weaknesses relative to competitors

Ultevursen Regulatory & Commercial Milestones

• Ultevursen Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Ultevursen Clinical Differentiation

• Ultevursen Efficacy & safety advantages over existing drugs
• Ultevursen Unique selling points

Ultevursen Market Report Highlights

• In the coming years, the Ultevursen market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Ultevursen companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Ultevursen’s dominance.
• Other emerging products for Retinitis pigmentosa and Usher syndromes are expected to give tough market competition to Ultevursen and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Ultevursen in potential indications.
• Analyse Ultevursen cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Ultevursen sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Ultevursen in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Ultevursen? How strong is Ultevursen’s clinical and commercial performance?
• What is Ultevursen’s clinical trial status in each individual indications such as Retinitis pigmentosa and Usher syndromes and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Ultevursen Manufacturers?
• What are the key designations that have been granted to Ultevursen for potential indications? How are they going to impact Ultevursen’s penetration in various geographies?
• What is the current and forecasted Ultevursen market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Ultevursen in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Ultevursen for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Ultevursen? What is the duration of therapy and what are the geographical variations in cost per patient?